Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Non-Randomized Phase 1 Dose Escalation and Dose Expansion Study of NIB101 in Participants With Advanced Solid Tumors

NCT05192174 is registered in ClinicalTrials.gov with Noile-Immune Biotech, Inc as lead sponsor.

NCT NCT05192174
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05192174 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Non-Randomized Phase 1 Dose Escalation and Dose Expansion Study of NIB101 in Participants With Advanced Solid Tumors
Lead sponsor
Noile-Immune Biotech, Inc
Phase
Phase 1
Overall status
Terminated
Start date
January 24, 2022
Completion date
May 16, 2025
Enrollment
3 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor